Abbvie Inc. · NYSE:ABBV
Abbvie — Merger or Acquisition (November 2023)
14 slides from Abbvie's merger presentation, Nov 30, 2023
Slide 1: Acquisition of ImmunoGen
Acquisition of ImmunoGen November 30, 2023 November 15, 2023 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation, including those relating to the proposed acquisition of ImmunoGen by AbbVie, are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
Slide 3: Strategic Rationale
Strategic Rationale Accelerates AbbVie’s entry into solid tumor space by providing a differentiated on-market drug for ovarian cancer, with ongoing late- stage development program to support expansion into larger treatment settings of ovarian cancer Maximizes ImmunoGen’s first-in-class folate recept
Slide 4: ImmunoGen Overview
ImmunoGen Overview Commercial-Stage Biotechnology Company Focused on the Discovery, Development and Commercialization of Antibody-Drug Conjugates for Cancer Patients • Long-standing history in ADCs • First-in-class FRa ADC, Elahere, FDA approved as a single agent for 2L+ ovarian cancer in the • Nove
Slide 5: Elahere Overview
Elahere Overview Anti-FRa ADC approved in the U.S. under accelerated approval pathway for 2L+ FRa high, platinum-resistant ovarian cancer First targeted agent to show overall survival benefit in platinum resistant patients Differentiated safety profile versus chemotherapy with fewer TEAEs/SAEs (e.g.
Slide 6: Ovarian Cancer Represents a Large and Underserved Market
Ovarian Cancer Represents a Large and Underserved Market ~85,000 ovarian cancer Ovarian cancer is the leading cause of drug-treated new patient starts death from gynecological cancers annually in US and EU5 5-Year Survival Rate of ~50% ~42,000 new patient starts are 2L+ (~45% PROC / ~55% PSOC) Major
Slide 7: Elahere Development Programs in Ovarian Cancer
Elahere Development Programs in Ovarian Cancer Expansion Opportunities in 2L+ Platinum-Sensitive, 1L Maintenance, FRa Medium Expressors • MARISOL Ph3 confirmatory study in FRa-high patients with PROC Platinum-Resistant • Positive top-line data demonstrating statistically significant improvement in O
Slide 8: ImmunoGen Pipeline
ImmunoGen Pipeline Novel pipeline targeting solid tumors and hematologic malignancies IMGN-151 PIVEKIMAB SUNIRINE Folate receptor alpha-targeting ADC CD123-targeting ADC Next-generation anti-FRa ADC designed for enhanced ADC with novel DNA alkylator payload designed for high payload delivery, cell k
Slide 9: ImmunoGen Development Programs
ImmunoGen Development Programs ADAM9: ADAM metallopeptidase domain 9; CD123: Interleukin-3 receptor alpha chain; FRa: Folate receptor alpha AML: Acute myeloid leukemia; BPDCN: Blastic plasmacytoid dendritic cell neoplasm; NSCLC: Non-small cell lung cancer; TNBC: Triple-negative breast cancer; Novemb
Slide 10: ADC Technology Synergies
ADC Technology Synergies Opportunity to complement AbbVie’s ADC technologies to develop compelling next-generation ADCs for a broad set of solid tumors types ImmunoGen brings 40+ years of experience in ADC development with unique targeted antibodies, optimized linkers for stability, and novel potent
Slide 11: ImmunoGen Highly Complementary to AbbVie's Solid Tumor Pipeline
ImmunoGen Highly Complementary to AbbVie’s Solid Tumor Pipeline Ovarian Lung CRC GEA PDAC HCC H&N TNBC Kidney MRPC Elahere (ADC) FRα (DM4 maytansinoid) Approved IMGN-151 (ADC) FRα (DM21 maytansinoid) Teliso-V (ADC) cMET (MMAE) ADCs ABBV-400 (ADC) cMET (TOP1i) and other targeted ABBV-706 (ADC) SEZ6 (
Slide 12: Transaction and Financial Overview
Transaction and Financial Overview • AbbVie has agreed to acquire all outstanding shares of ImmunoGen for a purchase price of $31.26 per share in all-cash transaction PURCHASE • Premium of approximately 95% to closing share price on November 29, 2023 PRICE • Purchase price of $10.1B; Implied transac
Slide 13: Key Takeaways
Key Takeaways Accelerates and strengthens AbbVie’s presence in solid tumors and contributes meaningful revenue growth over the next decade • Elahere represents a de-risked, on-market therapy with a proven survival benefit and strong launch trajectory in initial indication • Significant expansion opp
Slide 14: Oovobvie
Oovobvie